相关实验视频
Updated: Jul 7, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
类固醇诱导的高血糖症及其对R-CHOP化疗对扩散性大B细胞淋巴瘤的结果的影响
Mark Kristjanson1,2, Pascal Lambert3,4, Kathleen M Decker3,4,5
1Department of Family Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W2, Canada.
Current oncology (Toronto, Ont.)
|December 22, 2023
概括
在接受R-CHOP化疗的扩散性大B细胞淋巴瘤 (DLBCL) 患者中,类固醇诱导的高血糖症不会显著影响整体生存率或感染率. 高血糖症通常在治疗期间早期发展.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种积极的非霍奇金淋巴瘤 (NHL),用R-CHOP化疗治疗.
- 在R-CHOP中的类固醇通常会导致高血糖症,可能会影响患者的治疗结果.
- 化疗期间类固醇诱导的高血糖症与某些情况下的生存率降低有关.
研究的目的:
- 为了研究类固醇诱导的高血糖症对DLBCL患者治疗R-CHOP的结果的影响.
- 描述高血糖和感染率以及整体存活率之间的关系.
主要方法:
- 对188名用R-CHOP治疗的DLBCL患者的回顾性图表审查.
- 在2010-2014年间从癌症护理曼尼托巴 (CCMB) 收集的数据.
- 分析高血糖症,感染 (发烧性中性质疏松症) 和整体存活率 (OS).
主要成果:
- 过高血糖症在第一个R-CHOP周期的早期发展,对于受影响的患者来说.
- 在高血糖和低血糖组之间,整体存活率 (OS) 没有显著差异.
- 没有观察到感染率的显著差异,包括发烧性中性质疏松症.
结论:
- 在接受R-CHOP治疗的DLBCL患者中,类固醇诱导的高血糖症似乎不会显著降低整体存活率.
- 高血糖症的表现发生在治疗过程的早期.
- 进一步的研究可能会探索在DLBCL治疗中对类固醇诱导的高血糖症的管理策略.
相关概念视频
Hypoglycemia and Glucagon
266
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
266
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Insulin: Dosing Regimen and Adverse Effects
179
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
179
Diabetes: Symptoms, Diagnosis, and Complications
553
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
553
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Diabetes: Management and Pharmacotherapy
288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288

